• Cryptocurrencies
  • Voorspellingsmarkten
  • Nieuws
  • Agentisch Handelen
  • Artikelen
  • Competities

Zoeken Cryptocurrencies

Trends Cryptocurrencies

CoinRithm

Bedrijf

Rechtspersoon
Bees-x Limited
Bedrijfsnummer
13308136
Opgericht in
England and Wales
Statutaire zetel
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm is een informatie- en onderzoeksdienst van Bees-x Limited. Het is niet door de Financial Conduct Authority (FCA) gemachtigd om gereguleerde activiteiten uit te voeren, en niets op deze site vormt financieel advies.

Ontdekken

CryptocurrenciesVoorspellingsmarktenNieuwsArtikelenAgent ArenaCompetities

Functies

DashboardNephandelAgentisch HandelenPortefeuilleVolglijstInstellingen

Bedrijf

Over OnsMethodologieVoor de klasGebruiks- voorwaardenPrivacybeleidCookiebeleidVrijwaring

Ondersteuning

KlantenserviceFAQOntwikkelaarskitMCP-documentatie

Sociale Media

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Rechten voorbehouden.
Verkrijgbaar via Google PlayDownloaden in de App Store
  • Home
  • MarktenVoorspellingsmarkten
  • Nieuws
  • Dashboard
  1. Voorspellingsmarkten
  2. Health & Medicine
  3. Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)
Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)

Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)

1.0% (24u)One-OffHealth & MedicineWetenschap12d
KalshiKalshiBeschikbaarheid controlerenKYC vereist2% kosten
Huidige impliciete kans
Success
Success 17%-1.0%
Koploper van 5 uitkomsten
Marktkwaliteit

28 / 100

Lage kwaliteit
24u volume

€ 1

Liquiditeit

€ 5,4

Lage liquiditeit
Bied / Laat

16.0% / 23.0%

Spread

43.8%

Brede spread
Marktdata

Bijgewerkt 3 minuten geleden

10 jun 26, 0:001 jul 26, 3:59

Trends

Uitkomst24uKans

Gekozen uitkomst

Success17%

Regels

If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Success results in June 2026, the market resolves to Yes.

Kalshi
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Mixed results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Failure results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Ambiguous results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports No Results results in June 2026, the market resolves to Yes.

Gerelateerde Markten

Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

€ 994,6
Ja: 22.2%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Delivery Ritalin exists in one year?

€ 432,8
Ja: 7.5%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will there be a cure for schizophrenia before 2032?

€ 432,8
Ja: 11.8%Manifold MarketsMANIFOLD MARKETS
When will Beam Therapeutics submit a BLA for Risto-cel?

When will Beam Therapeutics submit a BLA for Risto-cel?

€ 0,9
before December: 54%KalshiKALSHI
When will Compass Pathways submit a NDA for COMP360 psilocybin?

When will Compass Pathways submit a NDA for COMP360 psilocybin?

€ 0,1
before October: 42%KalshiKALSHI
When will Intellia Therapeutics submit a BLA for Lonvo-z?

When will Intellia Therapeutics submit a BLA for Lonvo-z?

€ 0
before September: 46%KalshiKALSHI

Actief in deze onderwerpen

BitcoinBTC$63,931.19-2.89%EthereumETH$1,734.84-3.27%SolanaSOL$71.19-3.46%DogecoinDOGE$0.0847-3.23%XRPXRP$1.17-3.56%BNBBNB$592.24-2.19%

Gerelateerd Nieuws

NVIDIA BioNeMo Enables LoRA Fine-Tuning for Biotech ModelsBlockchain.NewsEthereum Researcher: Quantum-Proof Accounts Possible for $0.07Blockchain.NewsIBM Launches ffsim to Accelerate Fermionic Circuit SimulationsBlockchain.NewsAnthropic Targets AI-Driven Biology with gget Virus ToolBlockchain.NewsAnthropic’s Claude Tackles Chemistry with NMR Structure AnalysisBlockchain.NewsChainalysis reveals $100 million peptide market built on cryptoCrypto News

Regels

If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Success results in June 2026, the market resolves to Yes.

Kalshi
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Mixed results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Failure results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Ambiguous results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports No Results results in June 2026, the market resolves to Yes.